Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | IDH1 | O75874 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27547012 | 0.98 | L3MBTL1 (0.68) | L3MBTL1ALDH1A1HPGDLMNAHTT | |
| Hydrochloric Acid SCHEMBL11164652 | 0.98 | L3MBTL1 (0.68) | L3MBTL1ALDH1A1HPGDLMNAHTT | |
| SCHEMBL4622869 | 0.90 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1HPGDLMNAHTT | |
| SCHEMBL4237601 | 0.90 | L3MBTL1 (0.62) | L3MBTL1ALDH1A1HPGDLMNAHTT | |
| SCHEMBL4621396 | 0.90 | L3MBTL1 (0.58) | L3MBTL1ALDH1A1HPGDLMNAHTT | |
| SCHEMBL4237309 | 0.88 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1LMNAHTTMAOB | |
| SCHEMBL4242010 | 0.88 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1HPGDLMNAHTT | |
| SCHEMBL2419022 | 0.87 | L3MBTL1 (0.68) | L3MBTL1ALDH1A1HPGDLMNAHTT | |
| SCHEMBL7522410 | 0.85 | L3MBTL1 (0.71) | L3MBTL1ALDH1A1HPGDLMNAHTT | |
| SCHEMBL2814913 | 0.85 | L3MBTL1 (0.66) | L3MBTL1ALDH1A1HPGDLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | claimed |
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | claimed |
| EP-1904446-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | claimed |
| WO-2007007282-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-18 | — | — | WO | claimed |
| WO-2007005887-A2 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS, COMPOSITIONS AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-01-11 | — | — | WO | claimed |
| CN-111183130-A | Benzoheterocyclic derivatives and pharmaceutical compositions containing the same | 景凱生物科技股份有限公司 | 2020-05-19 | — | — | CN | disclosed |
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED | 2009-09-10 | — | — | US | disclosed |
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
| EP-1904446-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007007282-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-18 | — | — | WO | disclosed |
| US-4782080-A | ANALGESIC, ANTIINFLAMMATORY | MERCK & CO., INC. (US) | 1988-11-01 | — | — | US | disclosed |
| US-4771032-A | PHOTODECOMPOSING COLORING COMPONENTS COMPRISING A DIAZO COMPOUND AND COUPLER | FUJI PHOTO FILM CO., LTD. (JP) | 1988-09-13 | — | — | US | disclosed |
| EP-0014103-B1 | IMPROVED PROCESS FOR THE MANUFACTURE OF CARBAMATES | THE HALCON SD GROUP, INC. (US) | 1983-05-11 | — | — | EP | disclosed |
| US-4279637-A | Herbicidal N-substituted 4-imidazolin-2-ones | VELSICOL CHEMICAL CORPORATION (US) | 1981-07-21 | — | — | US | disclosed |
| US-4266070-A | CARBONYLS OF COBALT, MOLYBDENUM, TITANIUM, RHODIUM, IRON, NICKEL AND IRIDIUM AS CATALYSTS FOR THE CARBONYLATION OF PRIMARY OR SECONDARY AMINES AND ALCOHOLS TO FORM CARBAMATES | HALCON RESEARCH AND DEVELOPMENT CORP. (US) | 1981-05-05 | — | — | US | disclosed |
| US-4260781-A | Process for the manufacture of carbamates | HALCON RESEARCH AND DEVELOPMENT CORP. (US) | 1981-04-07 | — | — | US | disclosed |
| US-4258201-A | CATALYTIC CARBONYLATION OF PRIMARY OR SECONDARY AMINES WITH CARBON MONOXIDE AND ALCOHOLS | HALCON RESEARCH AND DEVELOPMENT CORP. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4242520-A | ONE-STEP CARBONYLATION OF AMINES IN THE PRESENCE OF A DISULFIDE | HALCON RESEARCH & DEVELOPMENT CORPORATION (US) | 1980-12-30 | — | — | US | disclosed |
| EP-0014103-A2 | Improved process for the manufacture of carbamates | THE HALCON SD GROUP, INC. (US) | 1980-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227571-A1 | Androgen Receptor Modulator Compounds and Methods | AR, NR5A1, ESRRA | L3MBTL1 4784/4885ALDH1A1 1408/4885HPGD 781/4885 |
| US-20090012116-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | L3MBTL1 4211/4885ALDH1A1 1806/4885HPGD 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.